肖碧莲与中国低剂量口服避孕药的研发  

Xiao Bi-lian and the Development of the Low-dose Oral Contraceptives in China

作　　者：陈珍晴 杨海燕[1] CHEN Zhen-qing;YANG Hai-yan(Institute for Medical Humanities,Peking University,Beijing 100191,China)

机构地区：[1]北京大学医学人文研究院,北京100191

出　　处：《医学与哲学（B）》2018年第3期94-97,共4页Medicine & Philosophy(B)

基　　金：2012年中国科学技术协会"肖碧莲院士学术成长资料采集工程"基金项目(2012-G-Z-XH17)

摘　　要：1969年中国通过了1/4剂量口服避孕药的鉴定,进而批量生产和推广使用,是当时世界上临床大量应用的最低剂量。生殖内分泌学家肖碧莲(1923-)是口服避孕药早期研发的重要领导者之一。本文回顾肖碧莲的学术成长经历以及对中国生殖内分泌学的奠基作用,重点梳理其团队的低剂量口服避孕药研发工作,从避孕药的剂量和剂型等变化考察社会经济条件对技术的具体形态的影响,尤其对技术的政治负载加以分析。In 1969,the low-dose oral contraceptives(1/4 of the conventional dosage)were approved in China.They were mass-produced and used nationwide,which were arguably the lowest dosage widely used in the world.Reproductive endocrinologist,Xiao Bi-Lian(1923-),is an important leader in the early development of oral contraceptives.This article reviews Xiao Bi-Lian's academic growth and her founding role in the establishment of reproductive endocrinology in China,with special focus on her team's endeavor in the development of low-dose oral contraceptives.It examines the shaping power of socio-economic conditions on the specific forms of technology,such as the dosage and formulation of contraceptives.In particular,the relation between technology and politics is analyzed.

关 键 词：低剂量口服避孕药 肖碧莲 技术与政治 

分 类 号：R169.41[医药卫生—公共卫生与预防医学]